TY - JOUR
T1 - Involvement of Both Tac and Non-Tac Interleukin 2-binding Peptides in the Interleukin 2-dependent Proliferation of Human Tumor-infiltrating Lymphocytes
AU - Yagita, Masato
AU - Itoh, Kyogo
AU - Tsudo, Mitsuru
AU - Schaub, Laurie B.Owen
AU - Platsoucas, Chris D.
AU - Balch, Charles M.
AU - Grimm, Elizabeth A.
PY - 1989/3/1
Y1 - 1989/3/1
N2 - Interleukin 2 (IL-2) receptor expression was examined on recombinant IL-2 (rIL-2)-propagated tumor-infiltrating lymphocytes (TIL) from eight metastatic melanoma and three sarcoma samples. All 11 TIL expanded with similar growth rates. rIL-2 propagated TIL from five of eight metastatic melanoma specimens contained no Tac antigen-positive lymphocytes as determined by immunofluorescence and flow cytometry performed multiple times during the 4 to 8 week culture period. However, Tac-negative TIL did express the non-Tac IL-2-binding peptide, p70–75 as determined by [125I]IL-2 cross-linking and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. IL-2-binding assays revealed that these “Tac-negative” TIL expressed only an intermediate affinity IL-2 receptor. In contrast, TIL from the other three of eight melanoma and all three sarcoma contained one-third Tac-positive cells as assessed by flow cytometry analysis, and expressed surface non-Tac (p70–75) and Tac (p55) peptides by [l25I]IL-2 cross-linking. These “Tac-positive” TIL displayed both the high and intermediate affinity IL-2 receptors. However, rIL-2-dependent growth of both “Tac-negative” and “Tac-positive” TIL was significantly inhibited by anti-Tac mAb, suggesting a transient Tac expression on the “Tac-negative” TIL. Additionally, due to the limits of our methodology, we cannot rule out the possibility of a constitutive expression of a low level of Tac, with an indicible expression of higher levels. Addition of culture supernatants from phytohemagglutinin- and phorbol myristate acetate-stimulated peripheral blood mononuclear cells to the “Tac-negative” TIL-induced detectable Tac expression within 48 h. These results indicate that both non-Tac and Tac IL-2 receptors play important roles during IL-2-dependent proliferation of TIL.
AB - Interleukin 2 (IL-2) receptor expression was examined on recombinant IL-2 (rIL-2)-propagated tumor-infiltrating lymphocytes (TIL) from eight metastatic melanoma and three sarcoma samples. All 11 TIL expanded with similar growth rates. rIL-2 propagated TIL from five of eight metastatic melanoma specimens contained no Tac antigen-positive lymphocytes as determined by immunofluorescence and flow cytometry performed multiple times during the 4 to 8 week culture period. However, Tac-negative TIL did express the non-Tac IL-2-binding peptide, p70–75 as determined by [125I]IL-2 cross-linking and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. IL-2-binding assays revealed that these “Tac-negative” TIL expressed only an intermediate affinity IL-2 receptor. In contrast, TIL from the other three of eight melanoma and all three sarcoma contained one-third Tac-positive cells as assessed by flow cytometry analysis, and expressed surface non-Tac (p70–75) and Tac (p55) peptides by [l25I]IL-2 cross-linking. These “Tac-positive” TIL displayed both the high and intermediate affinity IL-2 receptors. However, rIL-2-dependent growth of both “Tac-negative” and “Tac-positive” TIL was significantly inhibited by anti-Tac mAb, suggesting a transient Tac expression on the “Tac-negative” TIL. Additionally, due to the limits of our methodology, we cannot rule out the possibility of a constitutive expression of a low level of Tac, with an indicible expression of higher levels. Addition of culture supernatants from phytohemagglutinin- and phorbol myristate acetate-stimulated peripheral blood mononuclear cells to the “Tac-negative” TIL-induced detectable Tac expression within 48 h. These results indicate that both non-Tac and Tac IL-2 receptors play important roles during IL-2-dependent proliferation of TIL.
UR - http://www.scopus.com/inward/record.url?scp=0024505287&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024505287&partnerID=8YFLogxK
M3 - Article
C2 - 2783885
AN - SCOPUS:0024505287
SN - 0008-5472
VL - 49
SP - 1154
EP - 1159
JO - Cancer Research
JF - Cancer Research
IS - 5
ER -